Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
There are small buys printed at 36.65p. Controlled background buying is my suspicion. Only my opinion though. Not ramping or otherwise.
It is under 110,000 shares but over that its above 37p. Its not a huge number of shares to warrant such a jump in price given that lots of sells are being listed. Just seems different today.
The real buying price is 2 1/2 p cheaper though. Market games.
Odd price action this morning. Despite what looks to be a reasonable number of sells any larger share purchase over 110,000 is at a very significant premium. IG listing the buy price at 37p. Unusual.
I feel it is wrong and exceptionally insensitive and crass. I will keep encouraging investors to reject articlex9.
It is jist the wrong thing for all private shareholders.
We are excluded(!!) Why??
Outrageous.
Well said!
I still believe we should oppose resolution 9 which allows 100% dilution though.
I agree about the thresholds for Oxford being met. But I still think we should make sure we shareholders are not the sacrificial lambs by voting resolution 9 down.
Your post is however good.
Further to today's RNS, we are effectively satisfying 3 out of 4 criteria that would unlock the second instalment under the OF loan facility:
https://www.sec.gov/Archives/edgar/data/1830162/000149315221022583/ex10-14.htm (p.40 and see below)
(i) (A) PASSED!
(i) (B) THE STEP AWAY: we need one patient out of ten in non-small cell lung cancer cohort to see a clinical benefit
(ii) (EFFECTIVELY) PASSED: ASSUMING AT LEAST ONE PATIENT (!) GETS RECRUITED UNDER THE MRx0518/BAVENCIO PHASE II TRIAL WHICH IS NOW OPEN.
(iii) PASSED: POSITIVE TOPLINE DATA MRx4DP0004 ACHIEVED SO ROAD SHOULD BE OPEN TO PHASE B
"Second Draw Period Commencement Date” is the earliest date by which all of the following have been accomplished to Collateral Agent’s reasonable satisfaction: (i) Borrower achieving (A) positive data, including at least a 10% observed clinical benefit, in the Phase II trials of Borrower’s product candidate MRx0518 plus Keytruda in at least 20 patients with renal cell carcinoma (2 patients out of 20) and (B) positive data, including at least a 10% observed clinical benefit, from the non-small cell lung cancer cohort of at least 10 patients (1 patient out of 10); (ii) first patient dosed in Borrower’s product candidate MRx0518’s Urothelial Carcinoma Phase II trial in combination with Bavencio (avelumab); and (iii) Borrower’s product candidate Blautix advancing into a Phase 3 trial or Thetanix advancing into a Phase 2 trial, or Borrower achieving positive topline data sufficient to advance Borrower’s product candidate MRx4DP0004 into Part B of the Phase I trial in asthma. "
It would be very good news indeed if we end up receiving that non-dilutive funding from Oxford Finance which would provide a bridge into all the major milestones for late 2022 and 2023 possibly even into self financing! There might be other non-dilutive options though.